Medicamen Organics Ltd
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]
- Market Cap ₹ 48.0 Cr.
- Current Price ₹ 41.0
- High / Low ₹ 72.6 / 19.6
- Stock P/E 11.8
- Book Value ₹ 25.8
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 247 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 25.27 | 38.19 | |
| 20.53 | 31.61 | |
| Operating Profit | 4.74 | 6.58 |
| OPM % | 18.76% | 17.23% |
| 1.07 | 0.10 | |
| Interest | 0.65 | 0.51 |
| Depreciation | 0.72 | 0.74 |
| Profit before tax | 4.44 | 5.43 |
| Tax % | 40.77% | 25.41% |
| 2.62 | 4.05 | |
| EPS in Rs | 3.05 | 3.46 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 51% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 55% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -40% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 11.70 | |
| Reserves | 18.43 | |
| 12.36 | ||
| 16.72 | ||
| Total Liabilities | 59.21 | |
| 10.13 | ||
| CWIP | 2.22 | |
| Investments | 0.00 | |
| 46.86 | ||
| Total Assets | 59.21 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -3.66 | -4.54 | |
| -0.34 | -2.35 | |
| 4.01 | 10.47 | |
| Net Cash Flow | 0.02 | 3.58 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 247.06 | |
| Inventory Days | 127.51 | |
| Days Payable | 199.18 | |
| Cash Conversion Cycle | 175.39 | |
| Working Capital Days | 135.14 | |
| ROCE % |
Documents
Announcements
-
Updates
31 July 2025 - Disclosure of July 30, 2025 analyst meeting; no UPSI shared, routine compliance update.
-
General Updates
28 July 2025 - Medicamen appoints Nepalese actress Sanisha Bhattrai as LOIRE brand ambassador for Nepal market expansion.
-
Updates
25 July 2025 - Investor meeting scheduled virtually on July 30, 2025 at 4 PM IST.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
21 July 2025 - Certificate filed under SEBI regulation 74(5) for securities dematerialization for Q1 FY2026.
-
Press Release
8 July 2025 - Medicamen's subsidiary launches personal care products in Nepal, targeting ₹10 Cr sales and 50% CAGR over 5 years.
Annual reports
Concalls
-
Jun 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT
-
Jun 2024TranscriptNotesPPTREC
Business Overview:[1][2]
MOL specializes in manufacturing and distributing tablets, capsules, syrups, and ointments. It offers B2B contract and third-party manufacturing services for pharma companies in India and globally. Its portfolio includes generic and branded formulations, catering to government sectors, private institutions, and prominent pharma firms. Products are marketed via third-party distributors and loan licensing agreements.